2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells
Linlin Sun1, Xiuju Liu2, Haian Fu3
1Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, P.R. China.
Abstract:
Tumor cells rely on aerobic glycolysis to generate ATP, namely the "Warburg" effect. 2-deoxyglucose (2-DG) is well characterized as a glycolytic inhibitor, but its effect on cellular signaling pathways has not been fully elucidated. Herein, we sought to investigate the effect of 2-DG on ERK function in lung cancer cells. We found that 2-DG inhibits ERK phosphorylation in a time and dose-dependent manner in lung cancer cells. This inhibition requires functional LKB1. LKB1 knockdown in LKB1 wildtype cells correlated with an increase in the basal level of p-ERK. Restoration of LKB1 in LKB1-null cells significantly inhibits ERK activation. Blocking AMPK function with AMPK inhibitor, AMPK siRNA or DN-AMPK diminishes the inhibitory effect of 2-DG on ERK, suggesting that 2-DG-induced ERK inhibition is mediated by LKB1/AMPK signaling. Moreover, IGF1-induced ERK phosphorylation is significantly decreased by 2-DG. Conversely, a subset of oncogenic mutants of K-Ras, the main upstream regulator of ERK, blocks 2-DG-induced LKB1/AMPK signaling. These findings reveal the potential cross-talk between LKB1/AMPK and ERK signaling and help to better understand the mechanism of action of 2-DG.
Insights
The glycolytic inhibitor 2-deoxyglucose (2-DG) suppresses ERK phosphorylation in lung cancer cells via the LKB1/AMPK pathway. This reveals a novel cross-talk between metabolic regulation and cancer signaling.
Area of Science:
- Cellular metabolism
- Cancer biology
- Signal transduction
Background:
- Tumor cells exhibit aerobic glycolysis (Warburg effect) for ATP production.
- 2-deoxyglucose (2-DG) is a known glycolytic inhibitor.
- The precise impact of 2-DG on cellular signaling pathways, particularly ERK, remains unclear.
Purpose of the Study:
- To investigate the effect of 2-DG on ERK phosphorylation in lung cancer cells.
- To elucidate the underlying molecular mechanisms, including the role of LKB1 and AMPK.
Main Methods:
- Time- and dose-dependent analysis of ERK phosphorylation in response to 2-DG.
- LKB1 knockdown and restoration experiments in lung cancer cells.
- Assessment of AMPK pathway involvement using inhibitors and siRNA.
- Investigation of upstream regulators like K-Ras and IGF1.
Main Results:
- 2-DG inhibits ERK phosphorylation in a time- and dose-dependent manner.
- This inhibition is dependent on functional Liver Kinase B1 (LKB1).
- 2-DG-induced ERK inhibition is mediated by the LKB1/AMPK signaling pathway.
- Insulin-like Growth Factor 1 (IGF1)-induced ERK phosphorylation is reduced by 2-DG.
- Certain oncogenic K-Ras mutants interfere with 2-DG-mediated LKB1/AMPK signaling.
Conclusions:
- 2-DG exerts its inhibitory effect on ERK phosphorylation through the LKB1/AMPK pathway.
- A significant cross-talk exists between LKB1/AMPK metabolic signaling and ERK pathway activation in lung cancer.
- These findings enhance the understanding of 2-DG's mechanism of action and its potential in cancer therapy.
More Related Videos
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
MAPK Signaling Cascades
The Ras Gene
Ras is a...
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Abnormal Proliferation


